Advertisement
Research Article|Articles in Press

Non-esterified fatty acids and risk of peripheral artery disease in older adults: The cardiovascular health study

      Highlights

      • Higher non-esterified fatty acids (NEFAs) were significantly associated with incident clinical peripheral artery disease (PAD) over a long-term follow-up.
      • NEFAs may have a relationship with downstream consequences of progressive atherosclerosis.
      • NEFAs may represent part of the link between oxidative stress and resulting health outcomes like PAD.
      • This is the first study to longitudinally examine the association between NEFAs and PAD.

      Abstract

      Background and aims

      Non-esterified fatty acids have been implicated in the pathogenesis of diabetes and cardiovascular disease. No longitudinal study has assessed their effects on peripheral artery disease (PAD). We determined the relationships between NEFAs and incident clinical PAD and abnormal ankle-brachial index (ABI) in a population-based cohort of older persons.

      Methods

      We evaluated 4575 community living participants aged >65 years who underwent measurement of circulating NEFAs in fasting specimens and ABI in 1992–1993. Participants were assessed annually for clinical PAD until 2015 and underwent repeat ABI in 1998–1999. We used Cox proportional hazards regression to model the associations between NEFAs and risk of clinical PAD and logistic regression to model the associations of NEFAs with incident abnormal ABI.

      Results

      Mean age was 74.8 years, 59% were female, and 17% were Black. NEFAs were associated with higher risk of clinical PAD in unadjusted and adjusted models. The adjusted hazard ratios for incident clinical PAD were 1.51 (95%CI = 1.06–2.13, p = 0.02) across extreme tertiles, and 1.14 (95%CI = 0.99–1.31, p = 0.08) per standard deviation higher NEFA. The corresponding odds ratios for abnormal ABI were 0.95 (95%CI = 0.69–1.32, p = 0.76) across extreme tertiles, and 1.03 (95%CI = 0.89–1.20, p = 0.68) per standard deviation higher NEFA. Relationships appeared similar irrespective of sex, race, or pre-existing cardiovascular disease, but were stronger later than earlier in follow-up.

      Conclusions

      Higher serum levels of NEFAs are significantly associated with increased likelihood of clinical PAD over long-term follow-up but not with 6-year decline in ABI. NEFAs may offer a potential target for intervention against clinical PAD.

      Graphical abstract

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Campbell P.J.
        • Carlson M.G.
        • Hill J.O.
        • Nurjhan N.
        Regulation of free fatty acid metabolism by insulin in humans: role of lipolysis and re esterification.
        Am. J. Physiol. 1992; 263: 1063https://doi.org/10.1152/ajpendo.2006.263.6.E1063
        Date accessed: October 16, 2019
        • Ferrannini E.
        • Camastra S.
        • Coppack S.W.
        • Fliser D.
        • Golay A.
        • Mitrakou A.
        Insulin action and non-esterified fatty acids. the european group for the study of insulin resistance (EGIR).
        Proc. Nutr. Soc. 1997; 56 (S0029665197000293 [pii]): 753-761
        • Lv Z.
        • Ma P.
        • Luo W.
        • et al.
        Association between serum free fatty acid levels and possible related factors in patients with type 2 diabetes mellitus and acute myocardial infarction.
        BMC Cardiovasc. Disord. 2014; 14: 159https://doi.org/10.1186/1471-2261-14-159
        • Iozzo P.
        • Lautamaki R.
        • Geisler F.
        • et al.
        Non-esterified fatty acids impair insulin-mediated glucose uptake and disposition in the liver.
        Diabetologia. 2004; 47: 1149-1156https://doi.org/10.1007/s00125-004-1443-2
        Date accessed: October 16, 2019
        • Ahiawodzi P.
        • Djousse L.
        • Ix J.H.
        • et al.
        Non-esterified fatty acids and risks of frailty, disability, and mobility limitation in older adults: the cardiovascular health study.
        J. Am. Geriatr. Soc. 2020; 68: 2890-2897https://doi.org/10.1111/jgs.16793
        Date accessed: September 12, 2021
        • Pilz S.
        • Scharnagl H.
        • Tiran B.
        • et al.
        Free fatty acids are independently associated with all-cause and cardiovascular mortality in subjects with coronary artery disease.
        J. Clin. Endocrinol. Metab. 2006; 91: 2542-2547https://doi.org/10.1210/jc.2006-0195
        Date accessed: September 12, 2021
        • Miedema M.D.
        • Maziarz M.
        • Biggs M.L.
        • et al.
        Plasma-free fatty acids, fatty acid-binding protein 4, and mortality in older adults (from the cardiovascular health study).
        Am. J. Cardiol. 2014; 114: 843-848https://doi.org/10.1016/j.amjcard.2014.06.012
        Date accessed: September 12, 2021
        • Djoussé L.
        • Benkeser D.
        • Arnold A.
        • et al.
        Plasma free fatty acids and risk of heart failure: the cardiovascular health study.
        Circ Heart Fail. 2013; 6: 964-969https://doi.org/10.1161/CIRCHEARTFAILURE.113.000521
        Date accessed: September 12, 2021
        • Solaru K.
        Peripheral artery disease and african americans: review of the literature.
        Curr. Cardiovasc. Risk Rep. 2019; 13: 1-8https://doi.org/10.1007/s12170-019-0621-1
        • Steg P.G.
        • Bhatt D.L.
        • Wilson P.W.F.
        • et al.
        One-year cardiovascular event rates in outpatients with atherothrombosis.
        JAMA. 2007; 297: 1197-1206https://doi.org/10.1001/jama.297.11.1197
        Date accessed: September 12, 2021
        • Jones W.S.
        • Patel M.R.
        • Dai D.
        • et al.
        Temporal trends and geographic variation of lower-extremity amputation in patients with peripheral artery disease: results from U.S. medicare 2000-2008.
        J. Am. Coll. Cardiol. 2012; 60: 2230-2236https://doi.org/10.1016/j.jacc.2012.08.983
        Date accessed: September 12, 2021
        • McDermott M.M.
        • Liu K.
        • Greenland P.
        • et al.
        Functional decline in peripheral arterial Disease Associations with the ankle brachial index and leg symptoms.
        JAMA. 2004; 292: 453-461https://doi.org/10.1001/jama.292.4.453
        Date accessed: January 17, 2022
        • McDermott M.M.
        • Liu K.
        • Guralnik J.M.
        • et al.
        The ankle brachial index independently predicts walking velocity and walking endurance in peripheral arterial disease.
        J. Am. Geriatr. Soc. 1998; 46: 1355-1362https://doi.org/10.1111/j.1532-5415.1998.tb06001.x
        Date accessed: January 17, 2022
        • McDermott M.M.
        • Greenland P.
        • Liu K.
        • et al.
        The ankle brachial index is associated with leg function and physical activity: the walking and leg circulation study.
        Ann. Intern. Med. 2002; 136: 873-883https://doi.org/10.7326/0003-4819-136-12-200206180-00008
        Date accessed: January 17, 2022
        • McDermott M.M.
        Lower extremity manifestations of peripheral artery disease: the pathophysiologic and functional implications of leg ischemia.
        Circ. Res. 2015; 116: 1540-1550https://doi.org/10.1161/CIRCRESAHA.114.303517
        • Allison M.A.
        • Ho E.
        • Denenberg J.O.
        • et al.
        Ethnic-specific prevalence of peripheral arterial disease in the United States.
        Am. J. Prev. Med. 2007; 32: 328-333https://doi.org/10.1016/j.amepre.2006.12.010
        Date accessed: September 12, 2021
        • Criqui M.H.
        • Vargas V.
        • Denenberg J.O.
        • et al.
        Ethnicity and peripheral arterial disease: the san diego population study.
        Circulation. 2005; 112: 2703-2707https://doi.org/10.1161/CIRCULATIONAHA.105.546507
        Date accessed: September 12, 2021
        • Steinberg H.O.
        • Tarshoby M.
        • Monestel R.
        • et al.
        Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation.
        J. Clin. Invest. 1997; 100: 1230-1239
        • Shankar S.S.
        • Steinberg H.O.
        FFAs: do they play a role in vascular disease in the insulin resistance syndrome?.
        Curr. Diabetes Rep. 2005; 5: 30-35https://doi.org/10.1007/s11892-005-0064-6
        Date accessed: September 12, 2021
        • Sobczak A I.S.
        • Blindauer C A.
        • Stewart A J.
        Changes in plasma free fatty acids associated with type-2 diabetes.
        Nutrients. 2019; 11https://doi.org/10.3390/nu11092022
        • Shadid S.
        • Jensen M.
        Pioglitazone increases non-esterified fatty acid clearance in upper body obesity.
        Diabetologia. 2006; 49: 149-157
        • Franks P.W.
        • Wong M.
        • Luan J.
        • Mitchell J.
        • Hennings S.
        • Wareham N.J.
        Non-esterified fatty acid levels and physical inactivity: the relative importance of low habitual energy expenditure and cardio-respiratory fitness.
        Br. J. Nutr. 2002; 88: 307-313https://doi.org/10.1079/BJN2002663
        Date accessed: January 17, 2022
        • Chearskul S.
        • Delbridge E.
        • Shulkes A.
        • Proietto J.
        • Kriketos A.
        Effect of weight loss and ketosis on postprandial cholecystokinin and free fatty acid concentrations.
        Am. J. Clin. Nutr. 2008; 87: 1238-1246https://doi.org/10.1093/ajcn/87.5.1238
        Date accessed: September 6, 2021
        • Haus J.M.
        • Solomon T.P.J.
        • Marchetti C.M.
        • Edmison J.M.
        • González F.
        • Kirwan J.P.
        Free fatty acid-induced hepatic insulin resistance is attenuated following lifestyle intervention in obese individuals with impaired glucose tolerance.
        J. Clin. Endocrinol. Metab. 2010; 95: 323-327https://doi.org/10.1210/jc.2009-1101
        Date accessed: September 6, 2021
        • Björntorp P.
        • Bergman H.
        • Varnauskas E.
        Plasma free fatty acid turnover rate in obesity.
        Acta Med. Scand. 1969; 185: 351-356https://doi.org/10.1111/j.0954-6820.1969.tb07347.x
        Date accessed: September 4, 2021
        • Fried L.P.
        • Borhani N.O.
        • Enright P.
        • et al.
        The cardiovascular health study: design and rationale.
        Ann. Epidemiol. 1991; 1: 263-276https://doi.org/10.1016/1047-2797(91)90005-w
        Date accessed: September 12, 2021
        • Kennedy M.
        • Solomon C.
        • Manolio T.A.
        • et al.
        Risk factors for declining ankle-brachial index in men and women 65 years or older: the cardiovascular health study.
        Arch. Intern. Med. 2005; 165: 1896-1902https://doi.org/10.1001/archinte.165.16.1896
        Date accessed: December 3, 2020
        • Britton K.A.
        • Mukamal K.J.
        • Ix J.H.
        • et al.
        Insulin resistance and incident peripheral artery disease in the cardiovascular health study.
        Vasc. Med. 2012; 17: 85-93https://doi.org/10.1177/1358863x11436195
        • Psaty B.
        • Delaney J.
        • Arnold A.
        • et al.
        Study of cardiovascular health outcomes in the era of claims data: the cardiovascular health study.
        Circulation. 2016; 133: 156-164https://doi.org/10.1161/CIRCULATIONAHA.115.018610
        • Ives D.G.
        • Fitzpatrick A.L.
        • Bild D.E.
        • et al.
        Surveillance and ascertainment of cardiovascular events. the cardiovascular health study.
        Ann. Epidemiol. 1995; 5: 278-285
        Date accessed: October 16, 2019
        • Price T.R.
        • Psaty B.
        • O'Leary D.
        • Burke G.
        • Gardin J.
        Assessment of cerebrovascular disease in the cardiovascular health study.
        Ann. Epidemiol. 1993; 3: 504-507
        Date accessed: October 16, 2019
        • Cushman M.
        • Cornell E.S.
        • Howard P.R.
        • Bovill E.G.
        • Tracy R.P.
        Laboratory methods and quality assurance in the cardiovascular health study.
        Clin. Chem. 1995; 41: 264-270
        Date accessed: January 13, 2020
        • Arnold A.M.
        • Kronmal R.A.
        Multiple imputation of baseline data in the cardiovascular health study.
        Am. J. Epidemiol. 2003; 157: 74-84https://doi.org/10.1093/aje/kwf156
        • Cayatte A.J.
        • Kumbla L.
        • Subbiah M.T.
        Marked acceleration of exogenous fatty acid incorporation into cellular triglycerides by fetuin.
        J. Biol. Chem. 1990; 265: 5883-5888https://doi.org/10.1016/S0021-9258(19)39445-1
        • Huang N.K.
        • Bůžková P.
        • Matthan N.R.
        • et al.
        Associations of serum nonesterified fatty acids with coronary heart disease mortality and nonfatal myocardial infarction: the CHS (cardiovascular health study) cohort.
        J. Am. Heart Assoc. 2021; 10e019135https://doi.org/10.1161/JAHA.120.019135
        Date accessed: December 16, 2021
        • Ahiawodzi P.
        • Djousse L.
        • Ix J.H.
        • et al.
        Non-esterified fatty acids and risks of frailty, disability, and mobility limitation in older adults: the cardiovascular health study.
        J. Am. Geriatr. Soc. 2020; 68: 2890-2897https://doi.org/10.1111/jgs.16793
        Date accessed: December 22, 2021
        • Cui Y.
        • Li L.
        • Kang W.
        • Li Y.
        Exploring the effects of free fatty acids in rat serum on the coronary atherosclerotic plaque formation by the CT projection measurement results of compression sensor.
        Measurement. 2020; 158107749https://doi.org/10.1016/j.measurement.2020.107749
        • Björntorp P.
        • Bergman H.
        • Varnauskas E.
        Plasma free fatty acid turnover rate in obesity.
        Acta Med. Scand. 1969; 185: 351-356https://doi.org/10.1111/j.0954-6820.1969.tb07347.x
        Date accessed: September 29, 2021
        • Boden G.
        Role of fatty acids in the pathogenesis of insulin resistance and NIDDM.
        Diabetes. 1997; 46: 3-10
        Date accessed: September 4, 2021
        • Guo S.
        • Yan Y.
        • Mu L.
        • et al.
        Association of serum free fatty acids with hypertension and insulin resistance among rural Uyghur adults in far western China.
        Int. J. Environ. Res. Publ. Health. 2015; 12: 6582-6590https://doi.org/10.3390/ijerph120606582
        Date accessed: September 28, 2021
        • Sarafidis P.A.
        • Bakris G.L.
        Non-esterified fatty acids and blood pressure elevation: a mechanism for hypertension in subjects with obesity/insulin resistance?.
        J. Hum. Hypertens. 2007; 21: 12-19https://doi.org/10.1038/sj.jhh.1002103
        Date accessed: September 28, 2021
        • Bülow J.
        • Madsen J.
        • Højgaard L.
        Reversibility of the effects on local circulation of high lipid concentrations in blood.
        Scand. J. Clin. Lab. Invest. 1990; 50: 291-296https://doi.org/10.3109/00365519009091581
        Date accessed: September 28, 2021
        • Grekin R.J.
        • Vollmer A.P.
        • Sider R.S.
        Pressor effects of portal venous oleate infusion. A proposed mechanism for obesity hypertension.
        Hypertension. 1995; 26: 193-198https://doi.org/10.1161/01.hyp.26.1.193
        Date accessed: September 28, 2021
        • Egan B.M.
        • Hennes M.M.
        • Stepniakowski K.T.
        • O'Shaughnessy I.M.
        • Kissebah A.H.
        • Goodfriend T.L.
        Obesity hypertension is related more to insulin's fatty acid than glucose action.
        Hypertension. 1996; 27: 723-728https://doi.org/10.1161/01.hyp.27.3.723
        Date accessed: September 28, 2021
        • Fagot-Campagna A.
        • Balkau B.
        • Simon D.
        • et al.
        High free fatty acid concentration: an independent risk factor for hypertension in the paris prospective study.
        Int. J. Epidemiol. 1998; 27: 808-813https://doi.org/10.1093/ije/27.5.808
        Date accessed: September 28, 2021
        • Steinberg H.O.
        • Tarshoby M.
        • Monestel R.
        • et al.
        Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation.
        J. Clin. Invest. 1997; 100: 1230-1239https://doi.org/10.1172/JCI119636
        Date accessed: October 16, 2019
        • Steinberg H.O.
        • Paradisi G.
        • Hook G.
        • Crowder K.
        • Cronin J.
        • Baron A.D.
        Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production.
        Diabetes. 2000; 49: 1231-1238https://doi.org/10.2337/diabetes.49.7.1231
        Date accessed: September 28, 2021
        • Stojiljkovic M.P.
        • Zhang D.
        • Lopes H.F.
        • Lee C.G.
        • Goodfriend T.L.
        • Egan B.M.
        Hemodynamic effects of lipids in humans.
        Am. J. Physiol. Regul. Integr. Comp. Physiol. 2001; 280: 1674https://doi.org/10.1152/ajpregu.2001.280.6.R1674
        Date accessed: September 28, 2021
        • Lopes H.F.
        • Stojiljkovic M.P.
        • Zhang D.
        • Goodfriend T.L.
        • Egan B.M.
        The pressor response to acute hyperlipidemia is enhanced in lean normotensive offspring of hypertensive parents.
        Am. J. Hypertens. 2001; 14: 1032-1037https://doi.org/10.1016/s0895-7061(01)02166-5
        Date accessed: September 28, 2021
        • Lopes H.F.
        • Martin K.L.
        • Nashar K.
        • Morrow J.D.
        • Goodfriend T.L.
        • Egan B.M.
        DASH diet lowers blood pressure and lipid-induced oxidative stress in obesity.
        Hypertension. 2003; 41: 422-430https://doi.org/10.1161/01.HYP.0000053450.19998.11
        Date accessed: September 28, 2021
        • Davda R.K.
        • Stepniakowski K.T.
        • Lu G.
        • Ullian M.E.
        • Goodfriend T.L.
        • Egan B.M.
        Oleic acid inhibits endothelial nitric oxide synthase by a protein kinase C-independent mechanism.
        Hypertension. 1995; 26: 764-770https://doi.org/10.1161/01.hyp.26.5.764
        Date accessed: September 28, 2021
        • Kim F.
        • Tysseling K.A.
        • Rice J.
        • et al.
        Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKbeta.
        Arterioscler. Thromb. Vasc. Biol. 2005; 25: 989-994https://doi.org/10.1161/01.ATV.0000160549.60980.a8
        Date accessed: September 28, 2021
        • Lu G.
        • Greene E.L.
        • Nagai T.
        • Egan B.M.
        Reactive oxygen species are critical in the oleic acid-mediated mitogenic signaling pathway in vascular smooth muscle cells.
        Hypertension. 1998; 32: 1003-1010https://doi.org/10.1161/01.hyp.32.6.1003
        Date accessed: September 28, 2021
        • Stojiljkovic M.P.
        • Lopes H.F.
        • Zhang D.
        • Morrow J.D.
        • Goodfriend T.L.
        • Egan B.M.
        Increasing plasma fatty acids elevates F2-isoprostanes in humans: implications for the cardiovascular risk factor cluster.
        J. Hypertens. 2002; 20: 1215-1221https://doi.org/10.1097/00004872-200206000-00036
        Date accessed: September 28, 2021
        • Zhang B.
        • Li M.
        • Zou Y.
        • et al.
        NFκB/Orai 1 facilitates endoplasmic reticulum stress by oxidative stress in the pathogenesis of non-alcoholic fatty liver disease.
        Front. Cell Dev. Biol. 2019; 7https://doi.org/10.3389/fcell.2019.00202
        • Kamceva G.
        • Arsova-Sarafinovska Z.
        • Ruskovska T.
        • Zdravkovska M.
        • Kamceva-Panova L.
        • Stikova E.
        Cigarette smoking and oxidative stress in patients with coronary artery disease.
        Open Access Maced. J. Med. Sci. 2016; 4: 636-640https://doi.org/10.3889/oamjms.2016.117
        • Grassi D.
        • Desideri G.
        • Ferri L.
        • Aggio A.
        • Tiberti S.
        • Ferri C.
        Oxidative stress and endothelial dysfunction: say NO to cigarette smoking.
        Curr. Pharmaceut. Des. 2010; 16: 2539-2550https://doi.org/10.2174/138161210792062867
        Date accessed: September 28, 2021
        • Kershbaum A.
        • Bellet S.
        • Dickstein E.R.
        • Feinberg L.J.
        Effect of cigarette smoking and nicotine on serum free fatty acids.
        Circ. Res. 1961; 9: 631-638https://doi.org/10.1161/01.RES.9.3.631
        • Harman D.
        Aging: a theory based on free radical and radiation chemistry.
        J. Gerontol. 1956; 11: 298-300https://doi.org/10.1093/geronj/11.3.298
        Date accessed: September 28, 2021
        • Balaban R.S.
        • Nemoto S.
        • Finkel T.
        Mitochondria, oxidants, and aging.
        Cell. 2005; 120: 483-495https://doi.org/10.1016/j.cell.2005.02.001
        Date accessed: September 28, 2021
        • Criqui M.H.
        • Aboyans V.
        Epidemiology of peripheral artery disease.
        Circ. Res. 2015; 116: 1509-1526https://doi.org/10.1161/CIRCRESAHA.116.303849
        Date accessed: September 28, 2021
        • Hierons S.J.
        • Marsh J.S.
        • Wu D.
        • Blindauer C.A.
        • Stewart A.J.
        The interplay between non-esterified fatty acids and plasma zinc and its influence on thrombotic risk in obesity and type 2 diabetes.
        Int. J. Mol. Sci. 2021; 2210140https://doi.org/10.3390/ijms221810140
        • Sugiyama S.
        • Jinnouchi H.
        • Hieshima K.
        • et al.
        A pilot study of ezetimibe vs. atorvastatin for improving peripheral microvascular endothelial function in stable patients with type 2 diabetes mellitus.
        Lipids Health Dis. 2015; 14: 37https://doi.org/10.1186/s12944-015-0028-z